Kari Kustaa Alitalo (born 21 May 1952 in Kuopio [1]) is a Finnish MD and a medical researcher. He is a foreign associated member of the National Academy of Sciences of the US. [2] He became famous for his discoveries of several receptor tyrosine kinases (RTKs) [3] [4] [5] and the first growth factor capable of inducing lymphangiogenesis: vascular endothelial growth factor C (VEGF-C). [6] In the years 1996–2007 he was Europe's second most cited author in the field of cell biology. [7] Alitalo is currently serving as an Academy Professor for the Academy of Finland. [8]
Alitalo received the Leopold Griffuel Prize in 2002 [9] and the 2006 Louis-Jeantet Prize for Medicine. [10] He also received the 2005 Eric Fernström Foundation's Nordic Prize [11] and the 2009 In-Bev Baillet Latour Health Prize. [12] In 2014, he received the Dr. A.H. Heineken Prize for Medicine.
Kari Kustaa Alitalo (born 21 May 1952 in Kuopio [1]) is a Finnish MD and a medical researcher. He is a foreign associated member of the National Academy of Sciences of the US. [2] He became famous for his discoveries of several receptor tyrosine kinases (RTKs) [3] [4] [5] and the first growth factor capable of inducing lymphangiogenesis: vascular endothelial growth factor C (VEGF-C). [6] In the years 1996–2007 he was Europe's second most cited author in the field of cell biology. [7] Alitalo is currently serving as an Academy Professor for the Academy of Finland. [8]
Alitalo received the Leopold Griffuel Prize in 2002 [9] and the 2006 Louis-Jeantet Prize for Medicine. [10] He also received the 2005 Eric Fernström Foundation's Nordic Prize [11] and the 2009 In-Bev Baillet Latour Health Prize. [12] In 2014, he received the Dr. A.H. Heineken Prize for Medicine.